What is the appropriate acute and suppressive treatment for a typical adult with recurrent herpes labialis, including options for pregnant patients and those with frequent recurrences?

Treatment of Herpes Labialis

Acute Episodic Treatment

For acute herpes labialis, initiate valacyclovir 2 g twice daily for 1 day (doses separated by 12 hours) at the earliest sign of prodromal symptoms or within 24 hours of lesion onset. 1

First-Line Oral Antiviral Options

• Valacyclovir 2 g twice daily for 1 day is the preferred first-line treatment, reducing median episode duration by 1.0 day compared to placebo with high-quality evidence. 1
• Famciclovir 1500 mg as a single dose provides equivalent efficacy to valacyclovir with the convenience of single-day dosing. 1
• Acyclovir 400 mg five times daily for 5 days remains effective but requires more frequent dosing, which may reduce adherence. 1

Critical Timing Considerations

• Treatment must be initiated during the prodromal phase (tingling, burning, itching) or within 24 hours of lesion appearance to achieve maximum benefit, as peak viral titers occur in the first 24 hours after lesion onset. 1
• Starting treatment after 24 hours markedly diminishes clinical efficacy, resulting in longer lesion duration and reduced symptom relief. 1
• Patient-initiated therapy at first symptoms may even prevent lesion development in some cases. 1

Important Clinical Considerations

• Topical antivirals provide only modest clinical benefit and are substantially less effective than oral therapy—they should not be used as primary treatment. 1
• Short-course, high-dose oral antiviral therapy offers greater convenience, cost benefits, and improved patient adherence compared to traditional longer courses. 1
• Provide patients with a prescription to keep on hand so treatment can be initiated immediately at first symptoms. 1

---

Suppressive Therapy for Frequent Recurrences

Patients experiencing six or more recurrences per year should be offered daily suppressive therapy, which reduces recurrence frequency by ≥75%. 1

First-Line Suppressive Options

• Valacyclovir 500 mg once daily (can increase to 1000 mg once daily for very frequent recurrences) 1
• Famciclovir 250 mg twice daily 1
• Acyclovir 400 mg twice daily 1

Indications for Suppressive Therapy

• Six or more recurrences per year 1
• Particularly severe, frequent, or complicated disease 1
• Significant psychological distress from recurrences 1

Duration and Monitoring

• Safety and efficacy have been documented for acyclovir for up to 6 years. 1
• Valacyclovir and famciclovir have documented safety for 1 year of continuous use. 1
• After 1 year of continuous suppressive therapy, consider discontinuation to reassess the patient's recurrence rate, as frequency decreases over time in many patients. 1

Important Limitations

• Suppressive therapy reduces but does not eliminate asymptomatic viral shedding. 1
• Topical antivirals are not effective for suppressive therapy as they cannot reach the site of viral reactivation in sensory ganglia. 1

---

Special Populations

Immunocompromised Patients

• Episodes are typically longer and more severe, potentially involving the oral cavity or extending across the face. 1
• May require higher doses or longer treatment durations. 1
• Acyclovir resistance rates are significantly higher (7% versus <0.5% in immunocompetent patients). 1
• For confirmed acyclovir-resistant HSV, foscarnet 40 mg/kg IV three times daily is the treatment of choice. 1

Severe Gingivostomatitis

• Mild cases: Acyclovir 20 mg/kg (maximum 400 mg/dose) orally three times daily for 5-10 days 1
• Moderate to severe cases requiring hospitalization: Acyclovir 5-10 mg/kg IV three times daily until lesions begin to regress, then switch to oral therapy and continue until lesions completely heal 1

Pregnant Patients

• While the provided guidelines do not specifically address pregnancy, oral acyclovir has the longest safety record and is generally considered acceptable for treatment of herpes labialis during pregnancy when clinically indicated. 1

Renal Impairment

• Dose adjustments are required based on creatinine clearance for acyclovir and valacyclovir to prevent nephrotoxicity. 1

---

Preventive Counseling

Trigger Avoidance

• Ultraviolet light exposure: Apply sunscreen (SPF 15 or higher) or zinc oxide to lips before sun exposure to decrease UV-triggered recurrences. 1, 2
• Counsel patients to identify and avoid personal triggers including fever, psychological stress, and menstruation. 1

Contagiousness and Transmission Prevention

• Active vesicular and ulcerative lesions are highly contagious. 1
• Patients remain contagious until all lesions are fully crusted, which is the standard clinical endpoint indicating substantial reduction in transmission risk. 1
• Avoid direct contact (kissing) and sharing items that contact the mouth (towels, utensils, lip balm) during active outbreaks. 1
• Even with optimal antiviral therapy, viral shedding persists for approximately 6.4 days with valacyclovir (versus 8.1 days without treatment). 1
• Asymptomatic viral shedding can occur even without visible lesions, meaning transmission risk never reaches absolute zero. 1

---

Common Pitfalls to Avoid

• Relying solely on topical treatments when oral therapy is significantly more effective 1
• Starting treatment too late—efficacy decreases significantly when treatment is initiated after lesions have fully developed 1
• Failing to consider suppressive therapy in patients with frequent recurrences (≥6 per year) who could significantly benefit 1
• Not discussing potential triggers (UV light, stress, fever) that patients should avoid even while on suppressive therapy 1
• Using inadequate dosing—not using short-course, high-dose therapy which is more effective than traditional longer courses 1

---

Safety and Tolerability

• All oral antivirals (acyclovir, valacyclovir, famciclovir) are generally well-tolerated with minimal adverse events. 1
• Common side effects include headache (<10%), nausea (<4%), and diarrhea, which are typically mild to moderate in intensity. 1
• Despite increasing use of HSV-specific antiviral agents, the incidence of resistant HSV-1 strains remains low (<0.5% in immunocompetent hosts). 1
• Development of resistance when oral antivirals are used episodically in immunocompetent patients is unlikely (<0.5%). 1